CA
NZ
UK
AU
IND
US
Kalshi's Bitcoin price market for Friday at 5pm EDT gives traders a multi-day window to price where BTC is likely to land relative to two key thresholds. At the time of the latest snapshot, the $66,000-or-above contract implied a 58% probability, notably higher than …
Kalshi's monthly market asking how high Bitcoin will get in July frames the question differently from the daily threshold markets: rather than pricing where BTC sits at a single point in time, it prices the probability that Bitcoin touches a given level at any …
Biohaven Ltd. (NYSE: BHVN) shares traded at $14.86, down 3.76% on the day, as the company prepares to present Phase 1 data for its solid tumor candidate BHV-1530 at the ESMO 2026 congress.
Standard BioTools Inc. (NASDAQ: LAB) shares traded at $0.85, down 5.02% on the day, as the company advances two Phase 1 oncology programs, TLN-121 and TLN-372, amid its pending merger with Treeline Biosciences, Inc.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares traded at $25.09, down 1.99% on the day, after the FDA granted Fast Track designation to remlifanserin, also known as ACP-204, under the RADIANT trial program for Alzheimer's disease psychosis.
Immunome Inc. (NASDAQ: IMNM) shares traded at $22.16, down 0.72% on the day, after the company disclosed that Phase 1 dosing has commenced for its immunotherapy candidate 177Lu-IM-3050.
Dogwood Therapeutics Inc. (NASDAQ: DWTX) shares traded at $1.38, unchanged on the day, after the company completed enrollment in its Phase 2b HALT-CINP trial evaluating Halneuron for chemotherapy-induced neuropathic pain.
BioLineRx Ltd. (NASDAQ: BLRX) shares traded at $2.83, down 2.41% on the day, as the company continues to advance GLIX1 in glioblastoma, with Phase 1/2 dosing underway.
Dyne Therapeutics Inc. (NASDAQ: DYN) shares traded at $23.45, down 1.22% on the day, as the company's zeleciment rostudirsen, also known as z-rostudirsen or DYNE-251, awaits a Priority Review PDUFA date of January 21, 2027, in the DELIVER trial program.
Scholar Rock Holding Corporation (NASDAQ: SRRK) shares traded at $50.66, down 4.16% on the day, as the company continues to advance two late-stage programs: SRK-181 in solid tumors and apitegromab in spinal muscular atrophy.
Please wait processing your request...